Genotypes of Hepatitis C Virus and Short Term Efficacy of alpha-nterferon Therapy in Patients with HCV Infection in Taegu.
- Author:
Jin Su CHOI
;
Heon Ju LEE
;
Young Du SONG
;
Soon Wook KWUN
;
Jong Yul EUN
;
Sun Taek CHOI
- Publication Type:Original Article
- Keywords:
HCV;
Interferon;
Genotype
- MeSH:
Daegu*;
Genetic Heterogeneity;
Genotype*;
Hepacivirus*;
Hepatitis C*;
Hepatitis*;
Humans;
Interferon-alpha;
Interferons;
Liver Diseases;
Platelet Count;
Polymorphism, Restriction Fragment Length;
Prevalence;
Prognosis
- From:The Korean Journal of Hepatology
1999;5(1):22-32
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: It has been reported that the difference in the hepatitis C virus (HCV) genotype due to genetic heterogeneity of HCV influence the clinical features, prognosis of HCV associated liver disease and response to interferon therapy. Prevalence of different genotypes of HCV may also vary between geographic areas. The aim of this study was to examine the relationship between the response to interferon alpha (IFN-a) therapy and HCV genotypes in patients with chronic HCV infection in Taegu and its environs. METHODS: One hundred seventy six patients known to be HCV antibody and HCV-NA positive were evaluated for HCV genotypes by restriction fragment length polymorphism. Among patients who had elevated ALT levels, 67 patients have been investigated for the role of the HCV genotype on disease outcome and the response of IFN-a therapy. RESULTS: Genotype 1b were found in 59.0% of patients (103/176), genotype 2a in 37.5% (66/176). The mode of transmission of HCV infection was guessed as transfusion in genotype 1b, but as parenteral infection in genotype 2a. According to their response to IFN-a therapy, 73 patients were divided into three groups, complete response, 18 (60%) of 30 patients with genotype 2a and 21 (48.8%) of 43 patients with genotype 1b: partial response, 5 (16.7%) of 30 patients with genotype 2a and 7 (16.2%) of 43 patients with genotype 1b: no response, 7 (23.3%) of 30 patients with genotype 2a and 15 (34.9%) of 43 patients with genotype 1b. Good response to IFN-a therapy was observed among patients group showing normal platelet count in patients with genotype 1b and normal GGT in patients with genotype 2a. CONCLUSIONS: The most frequently identified genotype was genotype 1b in Taegu and its environs, followed by genotype 2a. The HCV genotype was not a reliable predictor of response to IFN-a therapy. When a standardized regimen of IFN-a was administered, pretreatment serum platelet counts and GGT level seem to be useful predictor of IFN-a therapy in HCV infection. Further investigations are required in order to establish a correlation between viral factors and therapeutic responses.
